The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MLTX | -80% | -9.09% | -1.89% | -8% |
| S&P | +14.5% | +93.32% | +14.09% | +95% |
Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.
The Motley Fool analyzed 16 billionaire-led hedge funds to get an idea of their healthcare sector investment strategies.
A competitor's clinical trial stumble may be benefiting MoonLake.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.74M | -2539.4% |
| Market Cap | $3.00B | 8.4% |
| Market Cap / Employee | $29.96M | 0.0% |
| Employees | 100 | 100.0% |
| Net Income | -$56.05M | -126.4% |
| EBITDA | -$59.96M | -96.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $306.68M | -10.5% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $74.22M | 3570.0% |
| Short Term Debt | $1.55M | 17.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -35.06% | -24.6% |
| Return On Invested Capital | 64.98% | -22.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$54.53M | -95.5% |
| Operating Free Cash Flow | -$54.53M | -95.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 6.09 | 6.99 | 5.52 | 7.35 | 44.28% |
| Price to Tangible Book Value | 6.09 | 6.99 | 5.52 | 7.35 | 44.28% |
| Enterprise Value to EBITDA | -62.40 | -61.65 | -43.97 | -44.06 | -40.37% |
| Return on Equity | -17.7% | -25.2% | -30.6% | -40.3% | 271.45% |
| Total Debt | $3.38M | $2.83M | $75.60M | $75.77M | 2165.75% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
